中国のエゼチミブ市場2010-2019

◆英語タイトル:Investigation Report on China Ezetimibe Market, 2010-2019
◆商品コード:CRI5062930
◆発行会社(調査会社):China Research and Intelligence
◆発行日:2015年6月11日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:薬剤・医薬品・材料
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Enterprisewide(全社内共有可)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はChina Research and Intelligence社の日本における正規販売代理店です。China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Description

With the sustained economic development and the improvements in diet, Chinese people’s blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .
Ezetimibe, the first cholesterol absorption selective inhibitor in the world, was jointly developed by Merck and Schering-Plough and approved by FDA in 2002 as the first drug for regulating blood fat with completely innovative mechanism of action after statin. Ezetimibe can selectively inhibit cholesterol transporter in the small intestine, effectively reduce cholesterol absorption, lower plasma cholesterol level and decrease the amount of cholesterol normally available to liver cells. As an ideal partner of statin, ezetimibe can provide better control rates for LDL-C with good safety and tolerance than doubled statin dose or more potent statin.
Ezetimibe in the Chinese market is monopolized by Schering-Plough. Ezetimibe develops fast after entering China with annual sales rising from less than CNY 0.05 million in 2007 to CNY 20.67 million in 2014 and CAGR during this period reaching up to 137%.
Ezetimibe enjoys a vast demand in China and its market size is expected to grow in the next few years.

Readers can get at least the following information from this report:
-market size of ezetimibe in China
-price of ezetimibe in Chinese market
-market outlook of ezetimibe in China

The author suggests the following groups of people purchase this report:
-manufacturers of lipid-lowering drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service

【レポートの目次】

Table of Contents

1 Related Concepts of Ezetimibe
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Ezetimibe in China
2.1 Patent and Approval Status of Ezetimibe in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Ezetimibe in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Ezetimibe in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Ezetimibe in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Ezetimibe in Chinese Hospitals in 2014

7 Major Manufacturers of Ezetimibe in Chinese Market, 2010-2014

8 Market Outlook of Ezetimibe in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts

Chart Sales Status of Ezetimibe in China
Chart Sales Value of Ezetimibe in China, 2010-2014
Chart Sales Value of Ezetimibe in Some Regions in China, 2010-2014
Chart Sales Volume of Ezetimibe in China, 2010-2014
Chart Sales Volume of Ezetimibe in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (SI) in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Made by Schering-Plough (Ireland) in China, 2010-2014
Chart Sales Value and Market Share of Ezetimibe Tablets in China, 2010-2014
Chart Sales Volume and Market Share of Ezetimibe Tablets in China, 2010-2014
Chart Price of Ezetimibe Made by Schering-Plough (Singapore) in Some Chinese Cities in 2014



【掲載企業】

Schering-Plough

★調査レポート[中国のエゼチミブ市場2010-2019] (コード:CRI5062930)販売に関する免責事項を必ずご確認ください。
★調査レポート[中国のエゼチミブ市場2010-2019]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆